Gerresheimer achieved double-digit growth in sales and operating result in the financial year 2022. Sales increased organically by 16.2 percent to more than €1.8 billion, driven by all divisions. Operating profit grew organically by 10.2 percent to 338.4 million euros. Adjusted net profit for fiscal 2022 amounted to €151 million, compared to €133.1 million in the previous year.
“In 2022, Gerresheimer has proven that it is a profitable growth company, accelerating growth across all businesses. We have exceeded our targets, while steering Gerresheimer successfully through a dynamic environment. Our strategic investments from recent years are paying off, resulting in significantly higher growth rates and returns. We will continue to leverage business opportunities and to accelerate our profitable growth path”, said Dietmar Siemssen, CEO of Gerresheimer AG. “Following a strong close to 2022, we have made a good start to 2023. Our order books are at record levels, and we expect continued double-digit growth in revenue and adjusted EBITDA, while further improving margins”, he added.
Sales in the fourth quarter amounted to €529 million, corresponding to organic growth of 15.9 percent. The two business units Plastics & Devices and Primary Packaging Glass were the main contributors to this success. Operating profit rose by €17 million from €95 million in the previous year to €112 million, corresponding to organic growth of 11.9 percent after adjusting for foreign exchange. Sales in Plastics & Devices increased 13.8 percent organically in Q4 and 12.3 percent for the full year 2022, driven by strong demand for plastic packaging solutions, inhalers and pens. Operating profit increased 15.2 percent organically in Q4 and 8.8 percent in fiscal 2022. It amounted to €81 million in Q4 and €232 million in fiscal 2022. Primary Packaging Glass sales grew organically by 18.1 percent in Q4 and organically by 20.8 percent in fiscal 2022. This result was based on continued strong demand for container glass and high-quality glass containers such as "Gx Elite Glass" and "Gx RTF Vials." Operating profit improved organically by 8.9 percent for fiscal 2022. It reached €45 million in Q4 2022 and €162 million in fiscal 2022. The revenue contribution in the Advanced Technologies business unit of four million euros in Q4 was as expected, with a focus here on projects and investments for future growth. These include ongoing projects to develop a new pump for a biotech customer in the USA and a micropump for the treatment of chronic heart failure with SQ Innovation, which are well on track.
The implementation of the strategy and the achievement of the financial targets enable Gerresheimer to accelerate its sustainable, profitable growth. Growth projects, including a high level of new orders in the High Value Solutions and Medical Devices segments, are driving Gerresheimer's transformation into a systems and solutions provider and underlining the Company's position as a strategic partner of choice for the global pharma and biotech industry. In the financial year 2022, Gerresheimer consistently continued its investment program to accelerate profitable growth with a particular focus on High Value Solutions, Medical Devices and other growth initiatives. The company increased the capacity of "ready-to-fill" solutions for syringes and vials and built up the facilities for a new order for autoinjectors.
Gerresheimer is setting new standards for organic growth. The company will continue to consistently implement its "formula g" strategy program and leverage its business and growth opportunities as well as invest in the right niche markets. For the financial year 2023, the company expects organic sales growth of at least ten percent and a higher operating result in the same range.
